

The final authenticated version is available online at: <https://doi.org/10.1055/s-0035-1560564>


Synthesis of Erythrochelin: A Hydroxamate-type Siderophore from *Saccharopolyspora erythraea*

Michiyasu Nakao
Shunsuke Tsuji
Syuji Kitaike
Shigeki Sano*

Graduate School of Pharmaceutical Sciences, Tokushima University, Sho-machi, Tokushima 770-8505, Japan

ssano@tokushima-u.ac.jp

[Click here to insert a dedication.](#)



Received:
Accepted:
Published online:
DOI:

Abstract Erythrochelin, a hydroxamate-type siderophore produced by *Saccharopolyspora erythraea*, is synthesized for the first time. A key building block of erythrochelin containing the 2,5-diketopiperazine ring is prepared by intramolecular cyclization of the corresponding dipeptide precursor derived from two kinds of protected δ -*N*-hydroxy-L-ornithines. Consecutive condensation of the building block with protected D-serine and protected δ -*N*-hydroxy-D-ornithine, followed by deprotection, furnishes erythrochelin.

Key words erythrochelin, rhodotorulic acid, siderophore, 2,5-diketopiperazine, electrospray ionization mass spectrometry

Erythrochelin (**1**), a hydroxamate-type tetrapeptide siderophore², was isolated as the first nonribosomal peptide synthetase (NRPS)-derived natural product of *Saccharopolyspora erythraea*.³ In 2010, two groups independently reported the isolation and structural characterization of **1** (Figure 1).⁴ Marahiel et al. identified the structure of **1** using a novel radio-LC-MS-guided genome mining methodology as well as NMR and MS analyses.^{1a} On the other hand, Leadlay et al. isolated **1** as the metabolic product of the cryptic NRPS cluster and determined the structure based on NMR analysis of the Ga(III) complex of **1**.^{1b} Both groups proposed that the chemical structure of **1** included a 2,5-diketopiperazine (2,5-DKP) ring derived from δ -*N*-acetyl- δ -*N*-hydroxy-L-ornithine and δ -*N*-hydroxy-L-ornithine. In addition, a dipeptide moiety comprised of D-serine and α -*N*-acetyl- δ -*N*-acetyl- δ -*N*-hydroxy-D-ornithine was presented. In the literature, a biosynthetic route was established *in vitro* for the generation of δ -*N*-acetyl- δ -*N*-hydroxy-L-ornithine starting from L-ornithine.⁵ However, there has been no report on the chemical synthesis of **1**, and the specific rotation value of **1** has not been established.





Figure 1 Chemical structures of erythrochelin (**1**), foroxymithine (**2**), and rhodotorulic acid (**3**).



Scheme 1 Synthesis of 2,5-DKP 9.

In 1985, foroxymithine (**2**), which has a very similar chemical structure to **1**, was isolated from cultures of *Streptomyces nitrosporeus* as an angiotensin-converting enzyme inhibitor.⁶ Interestingly, **2** was constructed from only L- α -amino acids, whereas corresponding L- and D- α -amino acids were contained in **1** as shown in Figure 1. Dolence and Miller achieved the total synthesis of **2**.⁷ They established the chemical structure of **2** by comparing the spectroscopic data, including the specific rotation, with that of the natural product. The stereochemical structure of **2** isolated from *Streptomyces narbonensis* was also confirmed by Marfey's analysis of the corresponding Ga(III) complex of **2**.⁸ The biosynthetic mechanism of **2** has been predicted based on the NRPS domain organization.⁹ In addition, rhodotorulic acid (**3**)¹⁰, a structurally related hydroxamate-type siderophore isolated from *Rhodotula pilimanae*, has been synthesized by several groups, including ours.¹¹ A series of siderophores—triornicin,¹² isotriornicin,¹³ dimerumic acid,¹⁴ coprogen,¹⁵ coprogen B,^{14a} and α -N-methyl coprogen^{14c,16}—are also known as hydroxamate-type siderophores. Each of these hydroxamate-type siderophores has a 2,5-DKP ring as a characteristic building block.¹⁷ In this report, we present the first synthesis of **1** as a step toward the certain confirmation of its full stereochemistry.

First, we investigated the preparation of the key building block **9** containing the 2,5-DKP ring as shown in Scheme 1. Protected amino acids as starting materials, α -N-Boc- δ -N-acetyl- δ -N-benzyloxy-L-ornithine [(S)-**4**]^{11b,d} and δ -N-benzyloxy- δ -N-(2,2,2-trichloroethoxy)carbonyl-L-ornithine methyl ester hydrochloride [(S)-**5**]^{11d} were prepared from Boc-L-Glu(OBn)-OH. Condensation of (S)-**4** with (S)-**5** using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl)

as a coupling reagent in the presence of 1-hydroxybenzotriazole (HOBT) and *N,N*-diisopropylethylamine (DIPEA) furnished the *N*-Boc-dipeptide methyl ester **6** in 96% yield. We then tried a one-pot conversion of **6** into 2,5-DKP **8** using microwave irradiation at 170 °C in a mixed solvent of water with methanol,^{11e} but **8** was obtained in only moderate yield (58%). Therefore, we investigated a stepwise construction of **8**. Deprotection of the Boc group of **6** with an excess amount of 4N HCl in dioxane afforded the dipeptide methyl ester hydrochloride **7** in 96% yield. Intramolecular cyclization of **7** on treatment with ammonia solution (2M in methanol) afforded the 2,5-DKP **8** in 86% yield. Then, reductive cleavage of the 2,2,2-trichloroethoxycarbonyl (Troc) group of **8** with an excess amount of zinc powder in the presence of 1 equivalent of trifluoroacetic acid (TFA) gave the key building block **9** in 76% yield.


We attempted the condensation of 2,5-DKP **9** with two protected D- α -amino acids toward the synthesis of **1** (Scheme 2). Condensation of **9** with Boc-D-Ser(OBn)-OH [(R)-**10**] using EDC·HCl as a coupling reagent afforded **11**. Deprotection of the Boc group of **11** with an excess amount of TFA provided **12** in 74% yield (two steps). Amine **12** was coupled with α -N-Boc- δ -N-acetyl- δ -N-benzyloxy-D-ornithine [(R)-**4**], which was prepared from Boc-D-Glu(OBn)-OH, to furnish **13** in 89% yield. Amine **14** was obtained by acidic deprotection of the Boc group of **13** in 78% yield. Acetylation of **14** with 2 equivalent of acetic anhydride gave **15** in 93% yield. Finally, catalytic hydrogenolysis of **15** under hydrogen with palladium on carbon (10 wt% loading) provided erythrochelin (**1**) in 46% yield by recrystallization from chloroform-methanol. The chemical structure of **1** was fully characterized by

spectroscopic methods and agreed well with the reported ^1H and ^{13}C NMR data.¹ In addition, the negative specific rotation value $\{[\alpha]_D^{24} -10.3$ (c 1.00, MeOH)} was observed.

To investigate the coordination pattern of **1** with Fe(III), electrospray ionization mass spectrometry (ESI-MS) was used for the detection of metal-chelate complexes.¹⁸ As a result, **1** was suggested to form a 1:1 complex with Fe(III) from m/z of 679.1879 $[(\text{M}-3\text{H})+\text{Fe}(\text{III})+\text{Na}]^+$ (calcd: m/z of 679.1876) in the presence of 1 equiv of iron(III) chloride.¹⁹ Furthermore, a similar 1:1 complex with Mg(II) was indicated from m/z of

648.2449 $[(\text{M}-2\text{H})+\text{Mg}(\text{II})+\text{Na}]^+$ (calcd: m/z of 648.2456) in the ESI-MS analysis with 1 equiv of magnesium(II) chloride.¹⁹

In conclusion, we have achieved the synthesis of erythrochelin (**1**) and determined its specific rotation. In addition, **1** was found to form a 1:1 complex with not only Fe(III) but also Mg(II) based on ESI-MS analysis. The present work will be valuable for the confirmation of the full stereochemistry of **1** isolated from *Saccharopolyspora erythraea* and for the synthesis of stereoisomers of **1** and their structurally related derivatives with various metal chelating abilities.



Scheme 2 Synthesis of erythrochelin (**1**).

The experimental section has no title; please leave this line here.

All melting points were determined on a Yanagimoto micro melting point apparatus and uncorrected. IR spectra were obtained using a JASCO FT/IR-6200 IR Fourier transform spectrometer. ^1H NMR (500 MHz) and ^{13}C NMR (125 MHz) spectra were recorded on a Bruker AV500

spectrometer, respectively. Chemical shifts are given in δ values (parts per million) using tetramethylsilane (TMS) as an internal standard. ESI-MS were recorded on a Waters LCT Premier spectrometer. Elemental combustion analyses were performed using a J-SCIENCE LAB JM10. Microwave-assisted reaction was performed utilizing an automated single-mode microwave synthesizer (Initiator™ 60; Biotage AB). All reactions were monitored by TLC employing 0.25-mm silica gel plates

(Merck 5715; 60 F₂₅₄). Column chromatography was carried out on silica gel [Kanto Chemical 60N (spherical, neutral)]. Anhydrous CH₂Cl₂ was used as purchased from Kanto Chemical. DIPEA was distilled prior to use. All other reagents were used as purchased.

Methyl (S)-5-((Benzyloxy)[(2,2,2-trichloroethoxy)carbonyl]amino)-2-((S)-5-[N-(benzyloxy)acetamido]-2-((tert-butoxycarbonyl)amino)pentanamido)pentanoate (6)

To a solution of (S)-4 (498 mg, 1.31 mmol) in anhydrous CH₂Cl₂ (6.5 mL) were added HOBt (177 mg, 1.31 mmol), DIPEA (226 μL, 1.31 mmol), EDC·HCl (376 mg, 1.96 mmol), and (S)-5 (608 mg, 1.31 mmol) at 0 °C under argon. The reaction mixture was allowed to warm to r.t. and stirred for 24 h. AcOEt (40 mL) was added to the reaction mixture, and then washed with 5% citric acid (10 mL), 1N HCl (10 mL), H₂O (10 mL) and brine (10 mL). The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The oily residue was purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (50:1)] to afford **6** (987 mg, 96%) as a colorless oil.

[α]_D²⁰ +5.1 (c 1.00, CHCl₃).

IR (neat): 3305, 2953, 1683, 1506, 1456, 1367 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 7.46–7.32 (m, 10H), 7.12–7.00 (m, 1H), 5.24 (brd, 1H), 4.93 (s, 2H), 4.87–4.76 (m, 4H), 4.56–4.48 (m, 1H), 4.42–4.31 (m, 1H), 4.27–4.12 (m, 1H), 3.65 (s, 3H), 3.54 (t, J = 6.5 Hz, 2H), 3.49–3.45 (m, 1H), 2.10 (s, 3H), 1.89–1.63 (m, 7H), 1.55–1.46 (m, 1H), 1.43 (s, 9H).

¹³C NMR (125 MHz, CDCl₃): δ = 173.3, 172.4, 172.3, 155.8, 155.1, 134.8, 134.2, 129.6, 129.2, 129.0, 128.82, 128.76, 128.5, 95.3, 79.6, 76.3, 75.1, 52.2, 52.1, 51.7, 49.1, 43.4, 30.7, 29.2, 28.3, 23.2, 23.0, 20.4.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₃₅H₄₇Cl₃N₄NaO₁₀: 811.2255; found: 811.2256.

Methyl (S)-2-((S)-2-Amino-5-[N-(benzyloxy)acetamido]pentanamido)-5-((benzyloxy)[(2,2,2-trichloroethoxy)carbonyl]amino)pentanoate Hydrochloride (7)

A mixture of **6** (1 g, 1.26 mmol) and 4N HCl in dioxane (6.3 mL, 25.3 mmol) was stirred at r.t. for 30 min. The reaction mixture was concentrated *in vacuo*. The residue was washed with *n*-hexane and CHCl₃ to afford **7** (881 mg, 96%) as a white solid.

[α]_D²¹ +4.7 (c 1.00, CHCl₃).

IR (KBr): 3552, 3477, 3419, 3033, 2946, 2870, 1742, 1684 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.49 (brs, 3H), 8.26 (brd, 1H), 7.44–7.40 (m, 2H), 7.38–7.30 (m, 8H), 4.91 (s, 2H), 4.86–4.75 (m, 4H), 4.54–4.46 (m, 1H), 4.37 (brs, 1H), 4.02–3.87 (m, 1H), 3.69–3.47 (m, 3H), 3.59 (s, 3H), 2.06 (s, 3H), 2.10–1.72 (m, 8H).

¹³C NMR (125 MHz, CDCl₃): δ = 173.4, 171.9, 169.1, 155.1, 134.8, 134.2, 129.6, 129.3, 129.0, 128.8, 128.7, 128.5, 95.3, 77.1, 76.4, 75.2, 52.3, 52.2, 52.0, 48.8, 43.8, 28.53, 28.47, 23.3, 22.6, 20.4.

HRMS (ESI): *m/z* [M – HCl + Na]⁺ calcd for C₃₀H₃₉Cl₃N₄NaO₈: 711.1731; found: 711.1729.

2,2,2-Trichloroethyl Benzyloxy{3-((2S,5S)-5-{3-[N-(benzyloxy)acetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl}carbamate (8)

A mixture of **7** (53.0 mg, 0.073 mmol) and 2M NH₃ in MeOH (1.46 mL, 2.92 mmol) was stirred at r.t. for 20 h. The reaction mixture was concentrated *in vacuo*. The residue was filtered with CHCl₃ and concentrated *in vacuo*. It was then purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (15:1)] to afford **8** (41.5 mg, 86%) as a white solid.

Mp 146–147 °C (white powder, MeOH); [α]_D²¹ –29.8 (c 1.00, CHCl₃).

IR (KBr): 3190, 3058, 2951, 2899, 1708, 1678 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 7.44–7.32 (m, 10H), 6.88 (d, J = 1.0 Hz, 1H), 6.67 (d, J = 1.2 Hz, 1H), 4.92 (s, 2H), 4.82 (s, 2H), 4.80 (s, 2H), 4.00–3.91 (m, 2H), 3.73–3.58 (m, 2H), 3.57–3.45 (m, 2H), 2.07 (s, 3H), 1.95–1.68 (m, 8H).

¹³C NMR (125 MHz, CDCl₃): δ = 172.7, 168.1, 167.8, 155.2, 134.8, 134.3, 129.6, 129.2, 129.1, 128.9, 128.8, 128.6, 95.2, 76.5, 75.2, 54.5, 54.3, 49.1, 44.6, 31.0, 30.9, 22.71, 22.67, 20.5.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₂₉H₃₅Cl₃N₄NaO₇: 679.1469; found: 679.1462.

Anal. Calcd for C₂₉H₃₅Cl₃N₄O₇: C, 52.94; H, 5.36; N, 8.52. Found: C, 52.87; H, 5.32; N, 8.55.

N-(Benzyloxy)-N-{3-((2S,5S)-5-{3-[(benzyloxy)amino]propyl}-3,6-dioxopiperazin-2-yl)propyl}acetamide (9)

To a solution of **8** (1.16 g, 1.76 mmol) and zinc (1.73 g, 26.4 mmol) in anhydrous CH₂Cl₂ (17.6 mL) was added TFA (135 μL, 1.76 mmol) at 0 °C under argon. The reaction mixture was allowed to warm to r.t. and stirred for 1.5 h. The reaction mixture was filtered with CHCl₃ and 5% NaHCO₃ (20 mL) was added to the filtrate, and then extracted with CHCl₃ (30 mL x 3). The extract was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (20:1)] to afford **9** (650 mg, 76%) as a white solid.

Mp 94–95 °C; [α]_D²⁰ –52.5 (c 1.04, CHCl₃).

IR (KBr): 3033, 2926, 2890, 1665, 1456 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 7.43–7.28 (m, 10H), 6.70 (brs, 1H), 6.44 (brs, 1H), 5.57 (brs, 1H), 4.84–4.78 (m, 2H), 4.70 (s, 2H), 4.02–3.97 (m, 1H), 3.91–3.85 (m, 1H), 3.74–3.58 (m, 2H), 3.00–2.89 (m, 2H), 2.09 (s, 3H), 2.06–1.98 (m, 1H), 1.94–1.86 (m, 1H), 1.83–1.56 (m, 6H).

¹³C NMR (125 MHz, CDCl₃): δ = 172.5, 168.6, 168.4, 137.8, 134.3, 129.2, 129.0, 128.7, 128.5, 128.4, 127.9, 76.4, 76.1, 54.8, 54.4, 51.3, 44.7, 32.0, 31.1, 23.0, 22.7, 20.5.

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₆H₃₅N₄O₅: 483.2607; found: 483.2601.

tert-Butyl ((R)-3-(Benzyloxy)-1-((benzyloxy){3-((2S,5S)-5-{3-[N-(benzyloxy)acetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl}amino)-1-oxopropan-2-yl}carbamate (11)

To a solution of **9** (530 mg, 1.10 mmol) and (R)-**10** (649 mg, 2.20 mmol) in anhydrous CH₂Cl₂ (11 mL) was added EDC·HCl (442 mg, 2.31 mmol) at 0 °C under argon. The reaction mixture was allowed to warm to r.t. and stirred for 1 h. AcOEt (60 mL) was added to the reaction mixture, and then washed with 1N HCl (20 mL), H₂O (10 mL), 5% NaHCO₃ (20 mL), and brine (20 mL). The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The oily residue was purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (40:1 to 10:1)] to afford **11** (763 mg) as a colorless oil containing small amounts of impurities. In the next step, **11** was used without further purification.

¹H NMR (500 MHz, CDCl₃): δ = 7.41–7.34 (m, 10H), 7.31–7.20 (m, 5H), 6.50 (brs, 1H), 6.41 (brs, 1H), 5.49 (d, J = 8.4 Hz, 1H), 5.00 (brs, 1H), 4.94–4.76 (m, 4H), 4.52–4.44 (m, 2H), 4.00–3.82 (m, 2H), 3.76–3.58 (m, 5H), 3.54–3.45 (m, 1H), 2.08 (s, 3H), 1.91–1.83 (m, 1H), 1.79–1.67 (m, 7H), 1.45 (s, 9H).

¹³C NMR (125 MHz, CDCl₃): δ = 172.6, 171.6, 168.0, 167.7, 155.5, 137.6, 134.3, 133.9, 129.3, 129.2, 129.1, 129.0, 128.80, 128.76, 128.4, 127.79, 127.77, 79.8, 76.9, 76.5, 73.1, 70.0, 54.3, 54.1, 50.8, 44.8, 44.7, 30.7, 29.9, 28.4, 22.7, 22.1, 20.5.

(R)-2-Amino-N,3-bis(benzyloxy)-N-{3-((2S,5S)-5-{3-[N-(benzyloxy)acetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl}propanamide (12)

A solution of **11** (763 mg) in TFA (10 mL, 131 mmol) was stirred at r.t. for 30 min. The reaction mixture was concentrated *in vacuo*. The residue was dissolved in 5% NaHCO₃ (40 mL) and then extracted with CHCl₃ (25 mL x 3). The extract was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. It was then purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (15:1)] to afford **12** (534 mg, 74%, 2 steps) as a colorless oil.

[α]_D²⁰ -29.9 (c 1.00, CHCl₃).

IR (neat): 3452, 3244, 2936, 2871, 2516, 1664, 1454 cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 7.41-7.23 (m, 15H), 6.94 (brs, 1H), 6.90 (brs, 1H), 4.87-4.76 (m, 4H), 4.48 (s, 2H), 4.06 (brs, 1H), 3.93 (brs, 1H), 3.82 (brs, 1H), 3.76-3.57 (m, 5H), 3.55-3.49 (m, 1H), 2.06 (s, 3H), 1.91-1.65 (m, 10H).

¹³C NMR (125 MHz, CDCl₃): δ = 175.0, 172.6, 168.1, 168.0, 137.9, 134.3, 134.1, 129.3, 129.2, 129.1, 129.0, 128.80, 128.75, 128.4, 127.74, 127.70, 76.6, 76.5, 73.3, 72.7, 54.3, 54.2, 51.1, 44.7, 30.8, 30.4, 22.7, 22.5, 20.5.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₃₆H₄₅N₅NaO₇: 682.3217; found: 682.3210.

tert-Butyl ((5*R*,8*R*)-12-Acetyl-3-{3-((2*S*,5*S*)-5-{3-[*N*-(benzyloxy)acetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl}-5-[(benzyloxy)methyl]-4,7-dioxo-1,14-diphenyl-2,13-dioxo-3,6,12-triazatetradecan-8-yl)carbamate (13**)**

To a solution of **12** (44.1 mg, 0.0668 mmol) and (*R*)-**4** (25.4 mg, 0.0668 mmol) in anhydrous CH₂Cl₂ (0.7 mL) were added EDC·HCl (19.2 mg, 0.100 mmol) and 4-dimethylaminopyridine (DMAP) (0.82 mg, 0.00668 mmol) at 0 °C under argon. The reaction mixture was allowed to warm to r.t. and stirred for 24 h. AcOEt (20 mL) was added to the reaction mixture, and then washed with 1N HCl (5 mL), H₂O (5 mL), 5% NaHCO₃ (5 mL), and brine (5 mL). The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (20:1)] to afford **13** (60.6 mg, 89%) as a white solid.

Mp 52-55 °C; [α]_D²³ -31.9 (c 1.00, CHCl₃).

IR (KBr): 3064, 3034, 2931, 2869, 1708, 1675, 1497, 1454 cm⁻¹.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.17-8.09 (m, 3H), 7.48-7.34 (m, 15H), 7.31-7.19 (m, 5H), 6.89 (brd, 1H), 5.26-5.15 (m, 1H), 5.01-4.94 (m, 1H), 4.89-4.82 (m, 5H), 4.44-4.35 (m, 2H), 4.08-3.99 (m, 1H), 3.84-3.75 (m, 3H), 3.64-3.40 (m, 7H), 1.99 (s, 3H), 1.98 (s, 3H), 1.72-1.44 (m, 12H), 1.36 (s, 9H).

¹³C NMR (125 MHz, CDCl₃): δ = 173.2, 173.1, 172.7, 171.1, 168.3, 167.8, 155.8, 137.5, 134.4, 134.3, 134.1, 129.3, 129.25, 129.19, 129.06, 129.02, 129.0, 128.8, 128.7, 128.4, 128.0, 127.8, 79.5, 76.5, 76.3, 73.3, 69.2, 54.3, 53.6, 52.6, 49.9, 44.8, 44.3, 43.9, 30.4, 29.9, 28.4, 23.0, 22.7, 22.4, 20.5.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₅₅H₇₁N₇NaO₁₂: 1044.5058; found: 1044.5054.

(*R*)-2-Amino-*N*-{(*R*)-3-(benzyloxy)-1-((benzyloxy){3-((2*S*,5*S*)-5-{3-[*N*-(benzyloxy)acetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl)amino}-1-oxopropan-2-yl}-5-[*N*-(benzyloxy)acetamido]pentanamide (14**)**

A solution of **13** (60.6 mg, 0.0593 mmol) in TFA (0.6 mL, 7.86 mmol) was stirred at r.t. for 30 min. The reaction mixture was concentrated *in vacuo*. The residue was dissolved in 5% NaHCO₃ (7 mL) and then extracted with CHCl₃ (7 mL x 3). The extract was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (15:1)] to afford **14** (42.6 mg, 78%) as a colorless oil.

[α]_D²³ -25.8 (c 1.00, CHCl₃).

IR (neat): 3231, 2934, 2872, 1652, 1506, 1456 cm⁻¹.

¹H NMR (500 MHz, DMSO-*d*₆): 8.22 (brd, 1H), 8.14 (brd, 2H), 7.48-7.34 (m, 15H), 7.32-7.18 (m, 5H), 5.25-5.16 (m, 1H), 5.02-4.94 (m, 1H), 4.90-

4.80 (m, 5H), 4.44-4.35 (m, 2H), 3.84-3.74 (m, 3H), 3.67-3.44 (m, 7H), 3.23-3.17 (m, 1H), 1.983 (s, 3H), 1.980 (s, 3H), 1.82 (brs, 2H), 1.72-1.50 (m, 11H), 1.39-1.28 (m, 1H).

¹³C NMR (125 MHz, CDCl₃): δ = 175.6, 173.7, 172.6, 171.2, 168.2, 167.7, 137.6, 134.4, 134.3, 134.0, 129.4, 129.24, 129.19, 129.0, 128.9, 128.78, 128.76, 128.71, 128.4, 127.9, 127.8, 76.5, 76.3, 73.1, 69.5, 54.4, 54.3, 53.8, 49.3, 44.7, 44.4, 32.1, 30.7, 30.0, 23.2, 22.7, 22.2, 20.51, 20.48.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₅₀H₆₃N₇NaO₁₀: 944.4534; found: 944.4532.

(*R*)-2-Acetamido-*N*-{(*R*)-3-(benzyloxy)-1-((benzyloxy){3-((2*S*,5*S*)-5-{3-[*N*-(benzyloxy)acetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl)amino}-1-oxopropan-2-yl}-5-[*N*-(benzyloxy)acetamido]pentanamide (15**)**

To a solution of **14** (29.5 mg, 0.0320 mmol) in anhydrous CH₂Cl₂ (0.64 mL) was added Ac₂O (6 μ L, 0.0640 mmol) at r.t. under argon. The reaction mixture was stirred for 40 min. AcOEt (20 mL) was added to the reaction mixture, and then washed with 5% NaHCO₃ (5 mL x 2), H₂O (5 mL), and brine (5 mL). The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography [Silica Gel 60N: CHCl₃-MeOH (20:1)] to afford **15** (28.7 mg, 93%) as a white solid.

Mp 65-70 °C (white powder, CHCl₃-*n*-hexane); [α]_D²² -34.3 (c 1.00, CHCl₃).

IR (KBr): 3267, 3213, 3065, 3034, 2934, 2870, 1670, 1535, 1498, 1455 cm⁻¹.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.30 (brd, 1H), 8.139 (d, *J* = 9.9 Hz, 1H), 8.136 (d, *J* = 9.8 Hz, 1H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.47-7.35 (m, 15H), 7.31-7.20 (m, 5H), 5.23-5.14 (m, 1H), 5.02-4.95 (m, 1H), 4.89-4.82 (m, 5H), 4.44-4.36 (m, 3H), 3.83-3.75 (m, 3H), 3.64-3.39 (m, 7H), 1.985 (s, 3H), 1.978 (s, 3H), 1.83 (s, 3H), 1.72-1.42 (m, 12H).

¹³C NMR (125 MHz, CDCl₃): δ = 173.7, 173.4, 172.7, 171.4, 170.7, 168.9, 168.4, 137.4, 134.3, 134.2, 129.21, 129.17, 129.1, 129.0, 128.9, 128.8, 128.7, 128.4, 128.0, 127.9, 76.51, 76.46, 76.3, 73.4, 68.7, 54.2, 53.2, 50.4, 44.8, 44.0, 43.4, 30.3, 29.8, 29.6, 23.2, 23.0, 22.9, 22.6, 20.5.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₅₂H₆₅N₇NaO₁₁: 986.4640; found: 986.4631.

(*R*)-2-Acetamido-*N*-{(*R*)-3-hydroxy-1-((hydroxy){3-((2*S*,5*S*)-5-{3-[*N*-hydroxyacetamido]propyl}-3,6-dioxopiperazin-2-yl)propyl)amino}-1-oxopropan-2-yl}-5-[*N*-hydroxyacetamido]pentanamide [Erythrochelin (1**)]**

A mixture of **15** (155 mg, 0.161 mmol) and 10% Pd-C (17.1 mg, 0.0161 mmol) in MeOH (3.2 mL) was stirred at r.t. for 3.5 h under hydrogen. The reaction mixture was filtered and concentrated *in vacuo*. The residue was recrystallized from CHCl₃-MeOH to afford erythrochelin (**1**) (44.7 mg, 46%) as a **hygroscopic** white powder.

[α]_D²⁴ -10.3 (c 1.00, MeOH).

IR (KBr): 3109, 2930, 2872, 1671, 1536, 1457 cm⁻¹.

¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.82 (brs, 1H), 9.67 (brs, 1H), 9.66 (brs, 1H), 8.13 (brs, 1H), 8.08 (brs, 1H), 7.96 (d, *J* = 8.3 Hz, 1H), 7.74 (brd, 1H), 4.92-4.85 (m, 1H), 4.78 (brt, 1H), 4.36-4.29 (m, 1H), 3.81 (brs, 2H), 3.67-3.35 (m, 8H), 1.97 (s, 6H), 1.85 (s, 3H), 1.71-1.39 (m, 12H).

¹³C NMR (125 MHz, DMSO-*d*₆): δ = 171.5, 170.17, 170.15, 169.2, 169.1, 167.9, 167.8, 60.8, 53.7, 53.5, 52.05, 52.03, 47.0, 46.7, 46.6, 30.2, 30.0, 29.4, 23.0, 22.4, 22.0, 21.7, 20.2.

HRMS (ESI): *m/z* [M + Na]⁺ calcd for C₂₄H₄₁N₇NaO₁₁: 626.2762; found: 626.2762.

ESI-MS Analysis of Erythrochelin (1**)-Fe(III) Complex**

A solution of Fe(III)Cl₃ (0.21 mg) was prepared at 0.7 μ M in MeOH and added to an equimolar amount of **1** (0.79 mg). The mixture was further

diluted (1:1000 v/v) in MeOH before it was injected in the ESI source for MS analysis.

ESI-MS Analysis of Erythrochelin (1)–Mg(II) Complex

A solution of Mg(II)Cl₂ (0.09 mg) was prepared at 0.5 μM in MeOH and added to an equimolar amount of 1 (0.56 mg). The mixture was further diluted (1:1000 v/v) in MeOH before it was injected in the ESI source for MS analysis.

Acknowledgment

This work was supported in part by a JSPS KAKENHI Grant (Number 15K18829).

Supporting Information

Is there **Supporting Information** to be published? Click here to indicate YES or NO (text and links will be updated prior to publication).

Primary Data

Is there **Primary Data** to be associated with this manuscript? Click here to indicate YES or NO (text and links will be updated prior to publication).

References

- (1) (a) Robbel, L.; Knappe, T. A.; Linne, U.; Xie, X.; Marahiel, M. A. *FEBS J.* **2010**, *277*, 663. (b) Lazos, O.; Tosin, M.; Slusarczyk, A. L.; Boakes, S.; Cortés, J.; Sidebottom, P. J.; Leadlay, P. F. *Chem. Biol.* **2010**, *17*, 160.
- (2) (a) Howard, D. H. *Clin. Microbiol. Rev.* **1999**, *12*, 394. (b) Renshaw, J. C.; Robson, G. D.; Trinci, A. P. J.; Wiebe, M. G.; Livens, F. R.; Collison, D.; Taylor, R. J. *Mycol. Res.* **2002**, *106*, 1123. (c) Saha, R.; Saha, N.; Donofrio, R. S.; Bestervelt, L. L. *J. Basic Microbiol.* **2013**, *53*, 303. (d) Raymond, K. N.; Allred, B. E.; Sia, A. K. *Acc. Chem. Res.* **2015**, *48*, 2496.
- (3) (a) Xu, W.; Li, L.; Du, L.; Tan, N. *Acta Biochim. Biophys. Sin.* **2011**, *43*, 757. (b) Licon-Cassani, C.; Marcellin, E.; Quek, L.-E.; Jacob, S.; Nielsen, L. K. *Anton. Leeuw.* **2012**, *102*, 493.
- (4) Oves-Costales, D.; Challis, G. L. In *Drug Discovery from Natural Products*, RSC Drug Discovery Series No. 25; Genilloud, O.; Vicente, F. Ed.; The Royal Society of Chemistry: Cambridge, **2012**, 145.
- (5) Robbel, L.; Helmetag, V.; Knappe, T. A.; Marahiel, M. A. *Biochemistry* **2011**, *50*, 6073.
- (6) (a) Umezawa, H.; Aoyagi, T.; Ogawa, K.; Obata, T.; Iinuma, H.; Naganawa, H.; Hamada, M.; Takeuchi, T. *J. Antibiot.* **1985**, *38*, 1813. (b) Aoyagi, T.; Wada, T.; Iinuma, H.; Ogawa, K.; Kojima, F.; Nagai, M.; Kuroda, H.; Obayashi, A.; Umezawa, H. *J. Appl. Biochem.* **1985**, *7*, 388.
- (7) Dolence, E. K.; Miller, M. J. *J. Org. Chem.* **1991**, *56*, 492.
- (8) (a) Ahmad, M. Ph.D. thesis, University of Warwick, Coventry, UK (2011). (b) Kodani, S.; Komaki, H.; Suzuki, M.; Kobayakawa, F.; Hemmi, H. *Biometals* **2015**, *28*, 791.
- (9) Chen, Y.; Ntai, I.; Ju, K.-S.; Unger, M.; Zamdborg, L.; Robinson, S. J.; Doroghazi, J. R.; Labeda, D. P.; Metcalf, W. W.; Kelleher, N. L. *J. Proteome Res.* **2012**, *11*, 85.
- (10) Atkin, C. L.; Neilands, J. B. *Biochemistry* **1968**, *7*, 3734.
- (11) (a) Isowa, Y.; Takashima, T.; Ohmori, M.; Kurita, H.; Sato, M.; Mori, K. *Bull. Chem. Soc. Jpn.* **1972**, *45*, 1467. (b) Fujii, T.; Hatanaka, Y. *Tetrahedron* **1973**, *29*, 3825. (c) Widmer, J.; Keller-Schierlein, W. *Helv. Chim. Acta* **1974**, *57*, 1904. (d) Lee, B. H.; Gerfen, G. J.; Miller, M. J. *J. Org. Chem.* **1984**, *49*, 2418. (e) Nakao, M.; Fukayama, S.; Kitaike, S.; Sano, S. *Heterocycles* **2015**, *90*, 1309.
- (12) Frederick, C. B.; Szaniszló, P. J.; Vickrey, P. E.; Bentley, M. D.; Shive, W. *Biochemistry* **1981**, *20*, 2432.
- (13) Frederick, C. B.; Bentley, M. D.; Shive, W. *Biochem. Biophys. Res. Commun.* **1982**, *105*, 133.
- (14) (a) Burt, W. R. *Infect. Immun.* **1982**, *35*, 990. (b) Aniya, Y.; Ohtani, I. I.; Higa, T.; Miyagi, C.; Gibo, H.; Shimabukuro, M.; Nakanishi, H.; Taira, J. *Free Radical Biol. Med.* **2000**, *28*, 999. (c) Bertrand, S.; Larcher, G.; Landreau, A.; Richomme, P.; Duval, O.; Bouchara, J.-P. *Biometals* **2009**, *22*, 1019. (d) Tseng, W.-T.; Hsu, Y.-W.; Pan, T.-M. *Pharm. Biol.* **2016**, in press.
- (15) (a) Hantke, K. *Mol. Gen. Genet.* **1983**, *191*, 301. (b) Simionato, A. V. C.; de Souza, G. D.; Rodrigues-Filho, E.; Glick, J.; Vouros, P.; Carrilho, E. *Rapid Commun. Mass Spectrom.* **2006**, *20*, 193.
- (16) Bertrand, S.; Bouchara, J.-P.; Venier, M.-C.; Richomme, P.; Duval, O.; Larcher, G. *Med. Mycol.* **2010**, *48*, S98.
- (17) (a) Borthwick, A. D. *Chem. Rev.* **2012**, *112*, 3641. (b) Giessen, T. W.; Marahiel, M. A. *Front. Microbiol.* **2015**, *6*, 785. (c) Sano, S.; Nakao, M. *Heterocycles*, **2015**, *91*, 1349.
- (18) (a) Spasojević, I.; Boukhalfa, H.; Stevens, R. D.; Crumbliss, A. L. *Inorg. Chem.* **2001**, *40*, 49. (b) Nguyen-van-Duong, M. K.; Guillot, V.; Nicolas, L.; Gaudemer, A.; Lowry, L.; Spasojević, I.; Crumbliss, A. L. *Inorg. Chem.* **2001**, *40*, 5948. (c) Dell'mour, M.; Koellensperger, G.; Quirino, J. P.; Haddad, P. R.; Stanetty, C.; Oburger, E.; Puschenreiter, M.; Hann, S. *Electrophoresis* **2010**, *31*, 1201. (d) Dimkpa, C. *Endocytobiosis Cell Res.* **2016**, *27*, 7. (e) Pluháček, T.; Lemr, K.; Ghosh, D.; Milde, D.; Novák, J.; Havlíček, V. *Mass Spectrom. Rev.* **2016**, *35*, 35.
- (19) The ESI-MS spectrum is shown in Supporting Information.

Supporting Information

for

Synthesis of Erythrochelin: A Hydroxamate-type Siderophore from

Saccharopolyspora erythraea


Michiyasu Nakao, Shunsuke Tsuji, Syuji Kitaike, and Shigeki Sano*



Graduate School of Pharmaceutical Sciences, Tokushima University



Sho-machi, Tokushima 770-8505, Japan



1. ^1H and ^{13}C NMR spectra



2. Electrospray ionization mass spectra



1. ^1H and ^{13}C NMR spectra



























2. Electrospray ionization mass spectra

